Cambridge Investment Research Advisors, Inc. Anavex Life Sciences Corp. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 83,347 shares of AVXL stock, worth $727,619. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,347
Previous 20,273
311.12%
Holding current value
$727,619
Previous $115,000
678.26%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding AVXL
# of Institutions
188Shares Held
29.2MCall Options Held
894KPut Options Held
821K-
Black Rock Inc. New York, NY6.39MShares$55.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.68MShares$40.9 Million0.0% of portfolio
-
State Street Corp Boston, MA2.41MShares$21.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.87MShares$16.4 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.13MShares$9.91 Million0.0% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $680M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...